Statin initiation and treatment non-adherence following a first acute myocardial infarction in patients with inflammatory rheumatic disease versus the general population.

Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use ; Myocardial Infarction/*epidemiology ; Public Health/*statistics & numerical data ; Rheumatic Diseases/*drug therapy ; Rheumatic Diseases/*epidemiology; Adult ; Aged ; Aged, 80 and over ; Australia/epidemiology ; Female ; Humans ; International Classification of Diseases/statistics & numerical data ; Logistic Models ; Male ; Middle Aged ; Myocardial Infarction/complications ; Outcome Assessment, Health Care/statistics & numerical data ; Patient Compliance/statistics & numerical data ; Proportional Hazards Models ; Retrospective Studies ; Rheumatic Diseases/complications ; Survival Analysis

Introduction: To compare statin initiation and treatment non-adherence following a first acute myocardial infarction (MI) in patients with inflammatory rheumatic disease (IRD) and the general population.
Methods: We conducted a retrospective cohort study using a population-based linked database. Cases of first MI from July 2001 to June 2009 were identified based on International Classification of Diseases (ICD-10-AM) codes. Statin initiation and adherence was identified based on pharmaceutical claims records. Logistic regression was used to assess the odds of statin initiation by IRD status. Non-adherence was assessed as the time to first treatment gap using a Cox proportional hazards model.
Results: There were 18,518 individuals with an index MI over the time period surviving longer than 30 days, of whom 415 (2.2%) were IRD patients. The adjusted odds of receiving a statin by IRD status was significantly lower (OR =0.69, 95% CI: 0.55 to 0.86) compared to the general population. No association between IRD status and statin non-adherence was identified (hazard ratio (HR) =1.12, 95% CI: 0.82 to 1.52).
Conclusions: Statin initiation was significantly lower for people with IRD conditions compared to the general population. Once initiated on statins, the proportion of IRD patients who adhered to treatment was similar to the general population. Given the burden of cardiovascular disease and excess mortality in IRD patients, encouraging the use of evidence-based therapies is critical for ensuring the best outcomes in this high risk group.

Ann Rheum Dis. 2005 May;64(5):753-9. (PMID: 15374854)
Mayo Clin Proc. 2009 Oct;84(10):917-38. (PMID: 19797781)
Arthritis Rheum. 2006 Jul;54(7):2061-8. (PMID: 16802340)
BMC Res Notes. 2014 Apr 21;7:253. (PMID: 24751124)
N Engl J Med. 2005 Apr 7;352(14):1425-35. (PMID: 15755765)
Lancet. 1994 Nov 19;344(8934):1383-9. (PMID: 7968073)
Arthritis Care Res (Hoboken). 2012 Jun;64(6):809-16. (PMID: 22467274)
Am J Epidemiol. 1997 Mar 1;145(5):408-15. (PMID: 9048514)
Ann Rheum Dis. 2009 Jul;68(7):1131-5. (PMID: 18697777)
Ann Rheum Dis. 2010 Mar;69(3):579-81. (PMID: 19403516)
Circulation. 2003 Dec 16;108(24):2957-63. (PMID: 14676136)
Clin Ther. 2006 Sep;28(9):1411-24; discussion 1410. (PMID: 17062314)
Ann Rheum Dis. 2014 Nov;73(11):1990-6. (PMID: 23887287)
Circulation. 2003 Mar 11;107(9):1303-7. (PMID: 12628952)
Arthritis Rheum. 2004 Nov;50(11):3450-7. (PMID: 15529378)
J Am Coll Cardiol. 2011 May 10;57(19):e215-367. (PMID: 21545940)
Med J Aust. 2006 Mar 20;184(6):287-90. (PMID: 16548834)
Arthritis Res Ther. 2010;12(5):R183. (PMID: 20929534)
Eur Heart J. 2012 Oct;33(20):2569-619. (PMID: 22922416)
Aust N Z J Public Health. 1999 Oct;23(5):453-9. (PMID: 10575763)
Intern Med J. 2013 Mar;43(3):227-34. (PMID: 23176380)
Curr Opin Rheumatol. 2007 Mar;19(2):190-6. (PMID: 17278937)
Curr Dir Autoimmun. 2001;3:188-99. (PMID: 11791466)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Lancet. 2005 Oct 8;366(9493):1267-78. (PMID: 16214597)
Mayo Clin Proc. 2009 Nov;84(11):1021-36. (PMID: 19880693)
Rheumatology (Oxford). 2004 Jan;43(1):7-12. (PMID: 12867578)
Med J Aust. 2009 Nov 16;191(10):539-43. (PMID: 19912085)
Ann Rheum Dis. 2012 Sep;71(9):1496-501. (PMID: 22402144)
Rheumatology (Oxford). 2008 May;47(5):578-83. (PMID: 18321944)
Ann Rheum Dis. 2011 Jun;70(6):1020-4. (PMID: 21378405)
J Rheumatol. 2014 Apr;41(4):723-9. (PMID: 24584925)
Heart Lung Circ. 2010 May-Jun;19(5-6):325-36. (PMID: 20363187)
N Engl J Med. 2004 Nov 11;351(20):2058-68. (PMID: 15531767)
Arthritis Rheum. 2002 Apr;46(4):862-73. (PMID: 11953961)
J Clin Epidemiol. 2004 Dec;57(12):1288-94. (PMID: 15617955)
J Eur Acad Dermatol Venereol. 2007 Jan;21(1):17-24. (PMID: 17207162)
Lancet. 2002 Apr 20;359(9315):1379-87. (PMID: 11978335)
J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. (PMID: 23845149)
Ann Rheum Dis. 2010 Feb;69(2):325-31. (PMID: 19773290)
Am J Med. 2008 Jan;121(1):43-9. (PMID: 18187072)
Int J Epidemiol. 2003 Aug;32(4):617-24. (PMID: 12913039)

0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)

Date Created: 20140927 Date Completed: 20150811 Latest Revision: 20240509

20240509

PMC4201728

10.1186/s13075-014-0443-y

25256139